High hopes for cannabinoid agonists in the treatment of rheumatic diseases

Staunton, Caroline A ORCID: 0000-0003-0647-3063, Mobasheri, Ali and Barrett-Jolley, Richard ORCID: 0000-0003-0449-9972 (2014) High hopes for cannabinoid agonists in the treatment of rheumatic diseases. BMC MUSCULOSKELETAL DISORDERS, 15 (1). 410-.

Text 1471-2474-15-410.pdf - Unspecified Download (592kB)

Abstract

There are two well-characterised isoforms of cannabinoid receptor; CB1 and CB2 and of these CB2 is under active investigation as a potential target for treatment of the chronic pain associated with widespread and intractable joint diseases osteoarthritis and rheumatoid arthritis. The recent report by Fukuda et al (BMC Musculoskelet Disord15:275, 2014) in BMC Musculoskeletal Disorders investigates the efficacy of a selective CB2 agonist, JW133, in both in vitro and in vivo models of rheumatoid arthritis and provides encouraging data. The report shows that JW133 inhibits expression of the CCL2 cytokine, osteoclastogenesis and reduces histological indicators of joint degeneration. Each of these could potentially contribute to beneficial analgesic effects in a therapeutic context.

Item Type:	Article
Uncontrolled Keywords:	Cannabinoids, Cannabis, Chronic pain, Dorsal root ganglia, Ion channels, Fibroblast-like synoviocytes (FLS), JW133, Osteoarthritis (OA), Rheumatoid Arthritis (RA)
Subjects:	?? QP ?? ?? RM ??
Depositing User:	Symplectic Admin
Date Deposited:	07 Apr 2015 09:11
Last Modified:	15 Dec 2022 16:25
DOI:	10.1186/1471-2474-15-410
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/2009622